论文部分内容阅读
选取DN90例,随机分为对照组和观察组各45例,对照组患者给予缬沙坦治疗,观察组患者给予缬沙坦联合贝那普利治疗。结果:治疗前,两组患者各项生理指标水平无明显差异(P>0.05),治疗后,两组患者SBP、DBP、Scr、UAIb水平均降低,(P<0.05),但观察组Scr、UAIb水平降低更加明显(P<0.05);两组患者不良反应发生率无明显差异(P>0.05)。结论:在DN的治疗中,应用缬沙坦及贝那普利联合治疗,能相互促进,改善肾功能,降低蛋白尿。
DN90 cases were selected and randomly divided into control group and observation group, 45 cases in each group. Patients in the control group were given valsartan. Patients in the observation group were treated with valsartan combined with benazepril. Results: The levels of SBP, DBP, Scr and UAIb in both groups decreased after treatment (P <0.05), but the levels of Scr, The level of UAIb decreased more obviously (P <0.05). The incidence of adverse reactions in the two groups had no significant difference (P> 0.05). Conclusion: In the treatment of DN, the combination of valsartan and benazepril can promote each other, improve renal function and reduce proteinuria.